This bidirectional regulation manifests in two ways: on one hand, ERS induces ICD through calreticulin exposure, HMGB1 release, and ATP secretion, enhancing anti-tumor immunity [104]; on the other hand, it promotes immune suppression via mechanisms such as PD-L1 glycosylation [103]. The gene discussed is HMGB1; the disease is neoplasm.